Treatment.com AI Announces New Additions to its Medical Education Suite (MES)
April 17 2024 - 3:05AM
Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (the
“
Company ” or “
Treatment ”) is excited to announce
two new solutions, (1)
AI Patient and (2)
AI Doctor in a
Pocket, to augment its Medical Education Suite (“
MES ”)
designed to educate the next generation of healthcare providers.
Treatment’s MES enhances the entire continuum of clinical
content education, from simple introductory patient interactions to
more advanced USMLE diagnostic evaluations and grading to complex
faculty benchmarking. It is designed to reduce faculty
administration costs and time, provide a comprehensive range of
clinical experiences, and offer students a digital self-test
companion to enhance their understanding of diagnostic clinical
approaches. The suite of solutions provides support for faculty and
students in both design and preparation for the OSCE (Objective
Structured Clinical Examination). This established clinical exam is
used in 57 countries to test the practical reasoning of healthcare
professional students and measure their progress in clinical
diagnosis and treatment.
The market in the US alone comprises 300 medical schools; 900
nursing schools; 227,000 students and 145,000 residents/medical
students. Treatment is also in discussions with schools in the UK
and Canada.
Treatment is excited to be announcing two new monthly
subscription-based SaaS solutions for students, residents and all
healthcare professionals expected to launch in the second half of
2024:
- AI Patient - utilizing AI and a library of test cases to
further support students in their preparation and readiness for
medical multiple-choice questions (MCQ’s) and OSCE exams.
- AI Doctor in a Pocket - delivers a mobile
friendly AI powered clinical decision support tool for healthcare
professionals and students when they are in clinics or on a
ward.
Both solutions are underpinned by Treatment’s AI powered
proprietary Global Library of Medicine (GLM), the most
comprehensive and integrated online medical library. The GLM has
been created with hundreds of credentialled clinicians globally to
ensure the highest qualified clinical information and support to
all healthcare professionals.
Dr. Essam Hamza, CEO of Treatment.com AI, comments: “I am
delighted to announce this extension to our portfolio of solutions,
especially given its focus on the next generation of clinicians.
Our goal is for students to be supported and excel during their
medical education, but can then utilize the same trusted platform
as they move into practice.”
Additionally, the Company has granted 800,000
Restricted Share Units (the “RSUs”), valid for a three-year term,
to consultants and an officer of the Company. The RSUs were issued
pursuant to the Company’s share compensation plan and a portion are
subject to vesting conditions. The RSUs are subject to a statutory
hold period of four months and one day from issuance.
About Treatment.com AI Inc.
Treatment.com AI is a company utilizing AI to positively disrupt
the healthcare sector and impact current inefficiencies and
challenges. Over the past 7+ years and with the input of hundreds
of healthcare professionals globally, Treatment.com AI has built
the world’s most intelligent, personalized healthcare AI engine,
the Global Library of Medicine (GLM). Providing the highest
qualified clinical information and support to all healthcare
professionals, the GLM delivers >92%+ accuracy on first
diagnosis as well as providing recommended tests (physical and
lab), x-rays, and billing codes. The platform’s quality and
transparency are unrivaled, as the GLM provides an explanation of
every step and likelihood associated with every symptom.
Treatment.com AI also focuses on the next generation of healthcare
professionals supporting Medical and Nursing schools, who utilize
the GLM to help enhance the future clinical skills of their
students. Treatment.com AI is focused on using AI for good and
utilizing its GLM platform to bring the possibility of health
equity and inclusion for disenfranchised communities.
FOR ADDITIONAL INFORMATION, CONTACT:
Dr. Essam Hamza, CEO
ehamza@treatment.com
If you would like to find out more about Treatment’s products
and services, please email at info@treatment.com
For media inquiries, contact: media@treatment.com
Call: +1 (612) 788-8900 / Toll-Free USA/Canada: +1 (888)
788-8955
Cautionary Statements
This news release contains forward-looking statements that are
based on Treatment.com AI’s expectations, estimates and projections
regarding its business and the economic environment in which it
operates, including with respect to the implementation of its
shareholder communications initiative and the timing thereof.
Although Treatment.com believes the expectations expressed in such
forward-looking statements are based on reasonable assumptions,
such statements are not guarantees of future performance and
involve risks and uncertainties that are difficult to control or
predict. Therefore, actual outcomes and results may differ
materially from those expressed in these forward-looking
statements, and readers should not place undue reliance on such
statements. These forward-looking statements speak only as of the
date on which they are made, and Treatment.com undertakes no
obligation to update them publicly to reflect new information or
the occurrence of future events or circumstances unless otherwise
required to do so by law.
The Canadian Securities Exchange does not accept responsibility
for the adequacy or accuracy of this release.